

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
26 February 2009 (26.02.2009)(10) International Publication Number  
**WO 2009/024823 A8**(51) International Patent Classification:  
*C07D 211/40* (2006.01) *C07D 295/18* (2006.01)  
*C07D 207/12* (2006.01)& D Wilmington, 1800 Concord Pike, PO Box 15437,  
Wilmington, Delaware 19850-5437 (US).(21) International Application Number:  
PCT/GB2008/050723(74) Agent: **ASTRAZENECA INTELLECTUAL PROP-  
ERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).(22) International Filing Date:  
20 August 2008 (20.08.2008)(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,  
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,  
SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/957,181 22 August 2007 (22.08.2007) US(71) Applicant (for all designated States except MG, US): **AS-  
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIM-  
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-  
don W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **ARNOLD, James**  
[US/US]; 96 Toledo Way, Apartment 305, San Francisco,  
California 94123 (US). **BRUGEL, Todd, Andrew**  
[US/US]; AstraZeneca R & D Wilmington, 1800 Concord  
Pike, PO Box 15437, Wilmington, Delaware 19850-5437  
(US). **EDWARDS, Phil** [US/US]; 1921 Marlboro Road,  
Kennett Square, Pennsylvania 19348 (US). **GRIFFIN,  
Andrew** [GB/CA]; AstraZeneca R & D Montréal, 7171  
Frédéric Banting, Saint Laurent, Québec H4S 1Z9 (CA).  
**GROBLEWSKI, Thierry** [FR/CA]; AstraZeneca R & D  
Montréal, 7171 Frédéric Banting, Saint Laurent, Québec  
H4S 1Z9 (CA). **LABRECQUE, Denis** [CA/CA]; As-  
traZeneca R & D Montréal, 7171 Frédéric Banting, Saint  
Laurent, Québec H4S 1Z9 (CA). **THRONEER, Scott** [US/  
US]; AstraZeneca R & D Wilmington, 1800 Concord  
Pike, PO Box 15437, Wilmington, Delaware 19850-5437  
(US). **WESOLOWSKI, Steven** [US/US]; AstraZeneca R(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:  
16 April 2009(48) Date of publication of this corrected version:  
18 March 2010(15) Information about Correction:  
see Notice of 18 March 2010

(54) Title: CYCLOPROPYL AMIDE DERIVATIVES



(I)

(57) Abstract: Disclosed herein is at least one cyclopropyl amide derivative of formula (I), at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.